“This quarter’s progress marks a steady period of advancement for Allarity (ALLR) as we have maintained a strong cash position, achieved record patient duration on stenoparib treatment, and welcomed new members to our leadership team who bring the expertise needed to shape a successful future for the Company,” said Thomas Jensen, CEO of Allarity Therapeutics. “We continue to drive the development of our promising, novel dual PARP/tankyrase inhibitor, stenoparib, forward, and we remain optimistic that our efforts will ultimately bring new hope to ovarian cancer patients, especially those who currently have few or no treatment options.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALLR:
- Allarity granted EPO for DRP companion diagnostic for stenoparib
- Allarity regains compliance with NASDAQ minimum bid price requirement
- ALLR Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Allarity names Jeremy Graff as president, CDO, Jose Iglesias as consultant CMO
- Allarity Therapeutics Strengthens Leadership for Cancer Programs